Exact Sciences (NASDAQ:EXAS) shares rose more than 2% after-hours following the company’s announced positive top-line results from the pivotal BLUE-C study.
The results show that next-generation Cologuard® met all study endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity.
The company plans to complete the FDA submission by the end of 2023.
"Once approved, next-generation Cologuard will meaningfully enhance the patient experience, and it comes at a critical time – when there are 60 million Americans not up to date with screening," said CEO Kevin Conroy.